OKYO revenueFY2026$32.1K
- FY YoY
- +486.5%
OKYO revenue was $32.1K for fiscal 2026 (ended Mar 31, 2026), up 486.5% from fiscal 2025.
OKYO Pharma Limited (OKYO) financials
For fiscal 2026 (ended Mar 31, 2026), OKYO Pharma Limited reported $32.1K of revenue and -$8.95M of net income.
- Revenue, FY2026
- $32.1K
- Revenue growth, YoY
- +486.5%
- Net income, FY2026
- -$8.95M
- Net margin
- -27882.3%
- Free cash flow, FY2026
- -$5.94M
- EPS, diluted, FY2026
- -$0.24
- Cash
- $14.59M
- P/S
- 2207.22
- Market cap
- $70.8M
FY2020FY2026
FY2020FY2026
FY2021FY2026
OKYO revenue and earnings growth
OKYO net incomeFY2026-$8.95M
OKYO net income was -$8.95M for fiscal 2026 (ended Mar 31, 2026), compared with -$4.71M in fiscal 2025.
OKYO EPSFY2026-$0.24
OKYO diluted EPS was -$0.24 for fiscal 2026 (ended Mar 31, 2026), compared with -$0.12 in fiscal 2025.
OKYO free cash flowFY2026-$5.94M
OKYO free cash flow was -$5.94M for fiscal 2026 (ended Mar 31, 2026), compared with -$1.81M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $32.1K | $5.5K | - | - | - | - | $48.1K |
| Research and development | $1.81M | $2.25M | $8.24M | $6.34M | $1.61M | $348.3K | $518.1K |
| Interest expense | $474.2K | $883.6K | $1.05M | $96.7K | - | $1.1K | $1.2K |
| Pre-tax income | -$8.94M | -$7.97M | -$16.80M | -$13.28M | -$6.22M | -$3.38M | -$1.62M |
| Income tax | -$8.0K | $3.26M | -$22.4K | $12.2K | $786.5K | $25.0K | $76.3K |
| Net income | -$8.95M | -$4.71M | -$16.83M | -$13.27M | -$5.43M | -$3.35M | -$1.54M |
| EPS, basic | -$0.24 | -$0.12 | -$0.57 | -$0.61 | -$0.36 | -$0.32 | - |
| EPS, diluted | -$0.24 | -$0.12 | -$0.57 | -$0.61 | -$0.36 | -$0.32 | - |
| Diluted shares | - | - | - | - | 979.2M | 672.8M | 595.5M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.59M | $1.56M | $826.8K | $4.05M | $2.70M | $6.89M | $235.5K |
| Receivables | - | - | - | $592.2K | $813.0K | $43.4K | - |
| Current assets | $20.97M | $3.68M | $1.54M | $5.20M | $4.30M | $6.99M | - |
| Total assets | $20.98M | $3.68M | $1.54M | $5.20M | $4.30M | $7.09M | - |
| Current liabilities | $8.64M | $9.23M | $7.42M | $7.26M | $1.35M | $1.71M | - |
| Total liabilities | $8.64M | $9.23M | $7.42M | $7.26M | $1.35M | $1.77M | - |
| Shareholders' equity | $12.34M | -$5.55M | -$5.88M | -$2.05M | $2.95M | $5.32M | -$140.1K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.94M | -$1.81M | -$9.49M | -$7.70M | -$5.47M | -$1.60M | -$1.20M |
| Capital expenditures | $6.1K | $1.2K | - | $5.9K | $1.7K | $6.9K | - |
| Free cash flow | -$5.94M | -$1.81M | - | -$7.70M | -$5.47M | -$1.61M | - |
| Investing cash flow | -$6.01M | -$1.2K | - | -$5.9K | -$1.7K | -$18.1K | -$132.7K |
| Financing cash flow | $25.02M | $2.66M | $6.21M | $9.32M | $2.15M | $7.83M | $963.3K |
| Stock-based compensation | $1.61M | $735.0K | $1.12M | $1.29M | $1.74M | $550.1K | $36.3K |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 486.5% | - | - | - | - | - | - |
| Net margin | -27882.3% | -85991.1% | - | - | - | - | -3208.4% |
| Free cash flow margin | -18512.0% | -33110.5% | - | - | - | - | - |
| Return on equity | -72.6% | - | - | - | -184.3% | -63.0% | - |
| Return on assets | -42.7% | -128.0% | -1091.7% | -255.0% | -126.3% | -47.3% | - |
| Current ratio | 2.43 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | - |
Source: XBRL data OKYO Pharma Limited files with the SEC, latest filing dated Jul 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
OKYO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| OKYO | $32.1K | +486.5% | -$8.95M | -27882.3% | $70.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.89B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $208.48B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $90.38B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.58B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.46B |
| RVMD | $0 | - | -$1.13B | - | $37.27B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.50B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $16.94B |
OKYO FAQ
8 questionsWhat is OKYO revenue?
OKYO Pharma Limited (OKYO) reported $32.1K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 486.5% from the year before.Is OKYO profitable?
No. OKYO Pharma Limited reported a net loss of $8.95M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does OKYO have?
OKYO Pharma Limited reported $14.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is OKYO revenue growing?
OKYO Pharma Limited's revenue changed +486.5% in fiscal 2026, to $32.1K.What is OKYO free cash flow?
OKYO Pharma Limited generated -$5.94M of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of -$5.94M less capital expenditures.What is OKYO earnings per share?
Diluted earnings per share were -$0.24 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did OKYO last report financial results?
The latest statements here come from OKYO Pharma Limited's 20-F filed on Jul 20, 2026, covering the period ended Mar 31, 2026.Where does this OKYO financial data come from?
Quantisnow builds these statements from the structured XBRL data OKYO Pharma Limited files with the SEC. It is provided for information only and is not investment advice.